Spero Therapeutics, Inc. (SPRO) Operating margin 2016–2025
Spero Therapeutics, Inc. (SPRO) operating margin by fiscal year — reported operating income divided by reported revenue.
50.2%FY2025 · since FY2016: -9916.7% → 50.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 50.2% | +19824.0 pp |
| FY2024 | -19773.9% | -22076.2 pp |
| FY2023 | 2302.4% | +3988.2 pp |
| FY2022 | -1685.9% | +1179.6 pp |
| FY2021 | -2865.5% | +27798.4 pp |
| FY2020 | -30664.0% | -29330.8 pp |
| FY2019 | -1333.1% | -253.8 pp |
| FY2018 | -1079.3% | +1029.3 pp |
| FY2017 | -2108.6% | +7808.1 pp |
| FY2016 | -9916.7% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice